Document is current
Any future updates will be listed below
-
Authors
Montesi, Sydney B.
Caravan, Peter
-
Funding
Funding for this research was provided by:
Scleroderma Foundation (N/A)
Parker B. Francis Foundation (N/A)
National Heart, Lung, and Blood Institute (HL131907, HL116315, HL109448)
- License Information
-
More Information
Article History
First Online: 25 April 2019
Compliance with Ethical Standards
:
: Sydney Montesi receives research support paid to her institution from United Therapeutics. She has received funding from Promedior though her institution. Peter Caravan has > 5% equity in Collagen Medical, Factor 1A LLC, and Reveal Pharmaceuticals. He receives research support from Pfizer, Pliant Therapeutics, Indalo Therapeutics, and has been a consultant to Collagen Medical. He is a named inventor on issued or pending patents that cover <sup>68</sup>Ga-CBP8, Gd-Hyd, and Gd-OA.Dr. Caravan reports grants from National Heart Lung and Blood Institute, during the conduct of the study; personal fees and other from Collagen Medical LLC, other from Reveal Pharmaceuticals, grants from Indalo Therapeutics, grants from Pliant Therapeutics, outside the submitted work; In addition, Dr. Caravan has a patent US2017360967 pending, and a patent WO2015085005 pending.
: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines). Figurehas not been published previously; however, the results from this image were published as part of Montesi et al. [•] with all appropriate informed consent obtained.
